Tumor Suppressors in Chronic Lymphocytic Leukemia: From Lost Partners to Active Targets

Cancers (Basel). 2020 Mar 9;12(3):629. doi: 10.3390/cancers12030629.

Abstract

Tumor suppressors play an important role in cancer pathogenesis and in the modulation of resistance to treatments. Loss of function of the proteins encoded by tumor suppressors, through genomic inactivation of the gene, disable all the controls that balance growth, survival, and apoptosis, promoting cancer transformation. Parallel to genetic impairments, tumor suppressor products may also be functionally inactivated in the absence of mutations/deletions upon post-transcriptional and post-translational modifications. Because restoring tumor suppressor functions remains the most effective and selective approach to induce apoptosis in cancer, the dissection of mechanisms of tumor suppressor inactivation is advisable in order to further augment targeted strategies. This review will summarize the role of tumor suppressors in chronic lymphocytic leukemia and attempt to describe how tumor suppressors can represent new hopes in our arsenal against chronic lymphocytic leukemia (CLL).

Keywords: PTEN; chronic lymphocytic leukemia; deletions; epigenetics; miRNA; mutations; p53; tumor suppressors.

Publication types

  • Review